Acrux presents at AusBiotech Invest
Released
Released
Announcement PDF
Acrux (ASX: ACR)
Michael Kotsanis
CEO and Managing Director
Australia Biotech Invest, Melbourne, October 2015
Forward-looking statements
This presentation includes forward-looking statements that are subject to risks and uncertainties.
Such statements involve known and unknown risks and important factors that may cause the actual results,
performance or achievements of Acrux to be materially different from the statements in this presentation.
Actual results could differ materially depending on factors such as the availability of resources, the results of
clinical studies, the timing and effects of regulatory actions, the strength of competition and the
effectiveness of patent protection.
2
Framework for continued growth
Pipeline projects
Improved chemical entities
Pipeline projects
Generic portfolio
Existing portfolio
2011
Timing of development
2025
3
Product Pipeline
Development
portfolio
Commercialised
portfolio
Indication
Product Name
Formulation
design
Pre-clinical
development
Phase 1
Phase 2
Phase 3
Registration
Commercial
Partner(s)
Hypogonadism
Axiron®
Eli Lilly
Menopausal
symptoms
Estradiol MDTS®
USA – Evamist®
Perrigo
Post-operative
pain in dogs
Recuvyra®
Elanco
Menopausal
symptoms
Estradiol MDTS®
Europe – Lenzetto®
Gedeon
Richter*
Onychomycosis
ACR-065
Diclofenac
ACR-046
Ibuprofen
ACR-048
Identified multiple
generics
Various
Initial generic
portfolio
Undisclosed
Companion animal
health
Undisclosed
*Ex-US licensees for Estradiol include Gedeon Richter, Aspen, Dream Pharma, Vifor. Trademarks vary by country/region.
Elanco
4
Acrux Generic Pipeline
Topical and Transdermal generic pipeline
Project: Multiple identified generic targets
Indication: various based on existing approved
and marketed drugs
Dosing: same as comparator
• Generic development opportunities identified through screen of
universe of marketed topical/transdermal products
• Initial products identified, development has been initiated
• For competitive reasons identified pipeline remains undisclosed
Generic pipeline leverages the existing technology, skills and
development infrastructure within Acrux
5
Acrux Once-a-Day Diclofenac Formulations
NSAID Development Program
Project: Topical diclofenac with superior delivery profile
Approved
comparator spray
3 doses
Acrux spray
1 dose
Approved comparator
gel 2 doses
Daily dose of Acrux Diclofenac formulation is 34-fold lower than approved comparator
spray however provides similar permeation profile
Single spray of Acrux formulation shown to match permeation profile of 15 sprays approved
comparator spray (maximum daily dose)
6
Acrux Once-a-Day Ibuprofen Formulations
NSAID Development Program
Project: Topical ibuprofen with superior delivery profile
Acrux Ibuprofen product formulations
demonstrate faster uptake through human skin
over existing competitor
7
Acrux Antifungal Proposition
Antifungal Development Program
Project: Antifungal Topical Product
Indication: For treatment of onychomycosis in
finger nails and toe nails
Formulation: Solution for topical administration
Dosing: Once a day
Target profile
•
Fast drying time with no residue
•
Once daily application
•
Easy and convenient delivery
•
Low systemic absorption
•
Better efficacy than comparator product
•
Long patent life, with new IP
Acrux is leveraging the existing technology, skills and development infrastructure
for its anti-fungal development
8
Financial Summary
FY15
FY14
Cash
23.1
25.8
Revenue
Milestone
Royalty
Other
Expenses
NPBT
NPAT
25.4
24.6
0.8
(8.6)
16.8
11.1
53.9
28.7
24.7
0.5
(10.0)
43.9
28.0
EPS (cents per share)
Dividends (cents per share)
6.7
6.0
16.8
20.0
• Dividend declared in August, paid September
6 cents per share, fully franked
4th consecutive annual dividend
• Strong balance sheet
$23.1 million cash on hand
Nil Debt
• Net Profit After Tax (NPAT) $11.1 million
• Earnings Per Share (EPS): 6.7 cents
• Forecast:
Half 1: Net operating cash inflow,
excluding dividend payment
No material increase in operating costs
Project costs to increase as projects
move to the clinic
9
Appendix follows
10
Financial Summary
$M
Comparison of year on year earnings
• FY14 Milestones received $28.7 million - $0.7M upon filing of Acrux’s estradiol spray in Europe;
$28.0 million upon achieving Axiron net sales hurdle
• Royalty payable to Monash Investment Trust declined, payable on Acrux’s product income
• Operating cost base well managed
11
Share your feedback
Discover